Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Topical Delgocitinib (JTE-052A) in Healthy Volunteers and Atopic Dermatitis Patients
jRCT2080222444Phase 1Completed
- Sponsor
- Japan Tobacco
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of delgocitinib in atopic dermatitis (AD) and Not applicable (entry is a general category, not a specific disease) (2 arms), sponsored by Japan Tobacco. Primary endpoints: Safety and tolerability of topical delgocitinib (JTE-052A) and Systemic exposure of delgocitinib (JTE-052A). Started Mar 2014; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)Not applicable (entry is a general category, not a specific disease)
Beyond the preview
Go deeper on jRCT2080222444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222444.